Swiss National Bank Reduces Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Swiss National Bank lessened its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 10.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 260,000 shares of the biopharmaceutical company's stock after selling 29,400 shares during the quarter. Swiss National Bank owned 0.20% of Halozyme Therapeutics worth $9,610,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. International Assets Investment Management LLC bought a new position in shares of Halozyme Therapeutics in the 4th quarter valued at $1,030,000. Harvey Capital Management Inc. acquired a new stake in Halozyme Therapeutics during the 4th quarter worth approximately $5,918,000. Hsbc Holdings PLC grew its holdings in Halozyme Therapeutics by 35.0% during the 3rd quarter. Hsbc Holdings PLC now owns 78,404 shares of the biopharmaceutical company's stock worth $3,006,000 after acquiring an additional 20,346 shares during the last quarter. Allspring Global Investments Holdings LLC increased its position in Halozyme Therapeutics by 174.5% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 887,274 shares of the biopharmaceutical company's stock valued at $33,894,000 after acquiring an additional 563,989 shares during the period. Finally, Aurora Investment Counsel bought a new position in shares of Halozyme Therapeutics during the third quarter valued at $1,347,000. Institutional investors and hedge funds own 97.79% of the company's stock.

Wall Street Analysts Forecast Growth

HALO has been the subject of a number of recent research reports. Benchmark restated a "buy" rating and issued a $50.00 price objective on shares of Halozyme Therapeutics in a report on Tuesday, April 16th. The Goldman Sachs Group dropped their price target on shares of Halozyme Therapeutics from $45.00 to $40.00 and set a "neutral" rating on the stock in a research report on Thursday, January 18th. HC Wainwright reiterated a "buy" rating and set a $50.00 price objective on shares of Halozyme Therapeutics in a research report on Tuesday, May 7th. JMP Securities decreased their price target on Halozyme Therapeutics from $72.00 to $71.00 and set a "market outperform" rating for the company in a report on Wednesday, May 8th. Finally, TheStreet lowered Halozyme Therapeutics from a "b-" rating to a "c+" rating in a research report on Monday, January 22nd. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Halozyme Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $53.14.

Halozyme Therapeutics Stock Up 1.1 %

NASDAQ:HALO traded up $0.46 on Monday, hitting $43.61. The stock had a trading volume of 908,619 shares, compared to its average volume of 1,214,816. The company has a quick ratio of 5.36, a current ratio of 6.64 and a debt-to-equity ratio of 8.44. Halozyme Therapeutics, Inc. has a 52 week low of $31.86 and a 52 week high of $45.00. The business's fifty day moving average is $40.26 and its 200 day moving average is $38.23. The company has a market cap of $5.55 billion, a PE ratio of 18.02, a P/E/G ratio of 0.48 and a beta of 1.26.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). Halozyme Therapeutics had a net margin of 36.94% and a return on equity of 225.71%. The business had revenue of $230.04 million during the quarter, compared to analyst estimates of $235.25 million. On average, equities research analysts expect that Halozyme Therapeutics, Inc. will post 3.43 EPS for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of the company's stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $39.55, for a total transaction of $395,500.00. Following the completion of the sale, the senior vice president now owns 156,558 shares in the company, valued at $6,191,868.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In the last quarter, insiders have sold 30,000 shares of company stock valued at $1,196,800. 2.40% of the stock is owned by corporate insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.